Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 13/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 13/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118029 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL29118030 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL18498189 | 0.72 | NAMPT (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL19211588 | 0.72 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL19211575 | 0.72 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL19211581 | 0.72 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL18498060 | 0.71 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL18498063 | 0.71 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL5241040 | 0.70 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL666529 | 0.70 | CHRNB2 (0.30) | CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022194122-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HCRTR1, HCRTR2, CCKBR | CHRNB2 776/4885CHRNB4 722/4885CHRNA3 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.